Trials Sponsors Conditions Drugs Pricing

Conditions

Hypocholesterolemia

Keywords

Angiopoietin-like protein 3 deficiencyLipid Metabolism

Outcome Measures

Primary Outcomes (3)

The role of ANGPTL3 on lipid metabolism.
Assessing ApoB-containing lipoprotein fractional catabolic rate
through study completion, an average of 13 weeks
The role of this protein on glucose metabolism.
Looking for glucose area under the curve following Oral Glucose Tolerance Test
through study completion, an average of 13 weeks
The role of ANPTL3 on fatty acids
Looking for fatty acids area under the curve following Oral Fat Tolerance Test
through study completion, an average of 13 weeks

Study Arms (2)

Variant

EXPERIMENTAL

Volunteers with known ANGPTL3 variants

Other: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Non-variant

OTHER

Healthy volunteers with no ANGPTL3 variants

Other: Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Interventions

Kinetics test, oral fat tolerance test, and an oral glucose tolerance test.Other

Subjects will participate in a kinetics test, oral fat tolerance test, and an oral glucose tolerance test.

Non-variantVariant

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Subjects aged 18 or older meeting at least one of the following criteria
Carrying genetic variants in the gene encoding for ANGPTL3,

Sponsors & Collaborators

National Heart, Lung, and Blood Institute (NHLBI)
NIHcollaborator
University of Pennsylvania
Otherlead

Study Sites (1)

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

RECRUITING

Lauren Vincent, MRACONTACT215-615-5448

Marina Cuchel, MD, PhDPRINCIPAL INVESTIGATOR

Study Officials

Marina Cuchel, MD, PhD
University of Pennsylvania
PRINCIPAL INVESTIGATOR

Central Study Contacts

Marina Cuchel, MD, PhD

CONTACT

215-662-7188 mcuchel@pennmedicine.upenn.edu

Study Design

Study Type: interventional
Phase: not applicable
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: OTHER
Intervention Model: PARALLEL
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

December 4, 2019

First Posted

January 21, 2020

Study Start

December 1, 2020

Actual (reported)

Primary Completion

June 30, 2026

Estimated (date passed)

This estimate has passed. The registry has not confirmed an actual date for this milestone.

Physiological Effects of ANGPTL3 Variants in Humans

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Study Arms (2)

Variant

Non-variant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (3)

Study Arms (2)

Variant

Non-variant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Study Officials

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source record

Documents

Locations